Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a randomized trial

Intranasal insulin (INI) has shown promise as a treatment for Alzheimer’s disease (AD) in pilot clinical trials. In a recent phase 2 trial, participants with mild cognitive impairment (MCI) or AD who were treated with INI with one of two delivery devices showed improved cerebral spinal fluid (CSF) b...

Descripción completa

Detalles Bibliográficos
Autores principales: Kellar, Derek, Register, Thomas, Lockhart, Samuel N., Aisen, Paul, Raman, Rema, Rissman, Robert A., Brewer, James, Craft, Suzanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789895/
https://www.ncbi.nlm.nih.gov/pubmed/35079029
http://dx.doi.org/10.1038/s41598-022-05165-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789895/
https://www.ncbi.nlm.nih.gov/pubmed/35079029
http://dx.doi.org/10.1038/s41598-022-05165-3

Ejemplares similares